Man-Made Antibodies Show Promise in Attacking Cancer Cells in Animal Models
DURHAM, N.C. -- Using chemotherapy along with aptamers -- lab-made molecules that function like antibodies -- Duke Health researchers showed that they can zero in on and kill prostate cancer tumors in mice while leaving healthy tissue unscathed.
The finding suggests that aptamers could form the basis of new cancer therapies if additional studies in animals and humans bear out.
“The benefit of aptamers compared to antibodies is that we have more control over where they go and what they do,” said senior author Bruce Sullenger, Ph.D., professor in the departments of Surgery and Pharmacology and Cancer Biology at Duke. “In our study, we also developed an antidote that shuts down the aptamer almost immediately, and this is an advantage if, for whatever reason, there might be an adverse reaction.”
Sullenger and colleagues -- including lead author Bethany Powell Gray, Ph.D., and co-author Linsley Kelly, Ph.D. -- published their findings online during the week of April 16 in the journal Proceedings of the National Academy of Sciences.
Man-made aptamers can be created to target cancer cells, much like the body’s naturally generated antibodies home in on pathogens such as viruses or bacteria. Recent drug advances have used antibodies in conjunction with chemotherapy to create immunotherapies that successfully fight cancer.
But inflammation and other side effects are common in these drug combinations, because it’s difficult to control where and how strongly the antibodies trigger immune responses outside of the cancer cells.
“A need exists for new tumor-targeting therapies that are easier to manipulate and synthesize,” Kelly said.
Aptamers are increasingly being studied as good alternatives. They are created using single RNA or DNA strands, which have the same targeting potential as antibodies, but appear to be nontoxic.
In their study on prostate cancer cells, the Duke team focused on an RNA ligand called E3, which selectively targets prostate cancer cells. They combined the E3 aptamer with a small dose of a highly toxic chemotherapy agent. Then they injected the aptamer/drug combination in mice that harbor human prostate cancer tumors.
Mice with prostate cancer tumors receiving the investigational treatment lived up to 74 days, compared to 46 days for mice that did not receive the treatment.
Additionally, the researchers developed an antidote to block toxicity from the E3 aptamer-drug conjugate, providing a safety switch in the unexpected event of normal cells being killed.
“That was one of the really exciting things from this work,” Powell Gray said. “Because they are single strands of RNA, they can be reversed by using a complimentary portion of RNA that will bind and make a double strand to unfold the aptamer.”
The researchers said studies will continue in animals and be tested in other types of cancer.
“This study demonstrates that E3 RNA selectively internalizes into prostate cancer cells
and that E3-highly toxic drug conjugates are potent anti-tumor agents, representing a potential new therapeutic approach,” Sullenger said.
In addition to Sullenger, Powell Gray and Kelly, study authors include Douglas Ahrens, Ashley Barry, Christina Kratschmer and Matthew Levy.
The research received funding support from the Department of Defense Prostate Cancer Research Program Post-Doctoral Training Award (PC131874) and Synergistic Idea Award (PC111812P2/W81XWH-12-1-0262), Stand Up to Cancer Innovative Research Grant (SU2C-AACR-IRG-0809) and National Cancer Institute grants (R21CA182330 and R21CA157366-03).